Forte Biosciences (NASDAQ:FBRX – Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.89) per share for the quarter.
Forte Biosciences Price Performance
Shares of FBRX opened at $6.38 on Friday. Forte Biosciences has a 1-year low of $4.11 and a 1-year high of $28.68. The stock has a market cap of $42.00 million, a price-to-earnings ratio of -0.39 and a beta of 2.82. The firm has a 50 day simple moving average of $6.62 and a 200-day simple moving average of $11.78.
Analysts Set New Price Targets
Several research firms have weighed in on FBRX. Chardan Capital dropped their price target on Forte Biosciences from $64.00 to $61.00 and set a “buy” rating for the company in a research report on Tuesday, April 1st. TD Cowen initiated coverage on shares of Forte Biosciences in a research note on Tuesday, January 21st. They issued a “buy” rating for the company.
About Forte Biosciences
Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.
Featured Articles
- Five stocks we like better than Forte Biosciences
- Basic Materials Stocks Investing
- GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?
- What is a support level?
- Here’s The Reason Goldman Sachs Is Bullish On MercadoLibre Stock
- Stock Market Upgrades: What Are They?
- Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?
Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
